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Recurrent Stroke in a Child with TRMA Syndrome and SLC19A2 Gene Mutation
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Here we report a 5-month-old boy with thiamine Responsive Megaloblastic 
Anemia syndrome (TRMA syndrome) with several attacks of stroke, 
admitted to Mofid Children’s Hospital, Tehran, Iran, in 2016. In addition to 
the cardinal clinical manifestations of the syndrome, other manifestations 
comprise thiamine-responsive megaloblastic anemia, diabetes mellitus, and 
sensor neural hearing loss. The patient showed the ischemic attack of stroke. 
Megaloblastic anemia and diabetes were diagnosed at 8 months and was 
successfully treated with vitamin and insulin prescription. After treatment of 
thiamine, diabetes was controlled and insulin was discontinued. In spite of the 
thiamine administration, the second stroke as hemorrhagic stroke occurred in 
the patient after a few months. TRAMA is inherited in an autosomal recessive 
manner. TRMA was confirmed by mutation in SLC19A2. A homozygous 
splice site variant was detected in SLC19A2 gene. Stroke was not reported in 
this syndrome (only in one report about one attack in an adult patient) but in 
this patient, several attacks of stroke were reported before and after thiamin 
administration.
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NEUROMETABOLIC DISORDER
Introduction
Thiamine-Responsive Megaloblastic Anemia syndrome (TRAMA syndrome) also 
known as ROGER syndrome is inherited in an autosomal recessive manner. Cardinal 
clinical manifestations of the syndrome include thiamine-responsive megaloblastic 
anemia, diabetes mellitus, and sensor neural deafness (1, 2). These symptoms do 
not appear in all of patient’s in distinct time, or all three manifests coincident (2). 
Additional findings include optic atrophy (3, 4), congenital heart disease (5), stroke 
(6), and short stature (3, 4). 
A splice site variant has detected in SLC19A2 gene locate on 1q23.3. It codes a protein 
that is necessary for thiamin uptake by cell (2). Mostly patient was homozygous for 
mutation in this gene but was described four patients with compound heterozygous 
mutation and novel mutation with the same symptom and response to thiamin (2). 
Reports revealed only one case with TRMA with stroke that she consumed oral 
contraceptives for ovarian cyst but she respond to thiamin therapy (6); however, our 
patient did not respond to thiamin well and he had stroke in spite of taking 300 mg of 
thiamin. Nevertheless, anemia and diabetes could be managed with this treatment.
Here we report a 5-month-old boy with TRMA syndrome with several attacks of 
stroke.
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TRMA syndrome was established for the patient and 
additional management included thiamine was started. 
Two months later (in spite of thiamine administration) 
the patient showed right-sided focal seizure. 
Now the patient is about 2.5 yrs old with bilateral 
optic atrophy, mild bilateral hemiplegia, and cognitive 
disorder. He is treated by antiepileptic drugs and 
300 mg thiamine per day. The last hematology and 
biochemical analysis showed normal blood sugar, 
normal lipid profile, and the hemoglobin concentration 
and MCV were 10 mg/dl and 75 fl, respectively. Gene 
analysis confirmed a homozygous splice in SLC19A2 
gene (Figure 1). The detected variant c.204+2T>G on 
SLC19A2 gene was validated in homozygous state in 
the patient. The genotypes of parents were heterozygote 
for this variant (Figure 2, 3). TRAMA is inherited in an 
autosomal recessive manner, and so the genotype of the 
patient was consistent with the mode of the inheritance 
of this disease. The detected variant was not reported 
in any of the population databases. MRI revealed left 
ischemic stroke in left MCA (Figure 4, 5). Enoxaparin 
sodium was prescribed for two months, but his parents 
stopped taking his medicine. 
Case presentation 
This study was conducted on a 5 months-old boy with 
focal seizure history, admitted to Mofid Children’s 
Hospital of Tehran, Iran in 2016. Declaration of informed 
consent was obtained from his parents. He was product 
of consanguineous marriage. The history of detecting of 
neurodevelopmental milestones was in normal limits. 
Brain magnetic resonance imaging (MRI) revealed 
hemorrhagic stroke in right Middle Cerebral Artery 
(MCA) region. Initially, the seizures were controlled by 
antiepileptic drugs. In addition, the patient showed left-
sided hemiplegia, regression in his neurodevelopmental 
milestones, and cognitive impairment. 
Results for complete lab tests for evaluation of 
stroke including, serum amino acid chromatography, 
antiphospholipid antibody, factor V Leiden and 
G20210A prothrombin, were not significant for 
collagen vascular disease, thrombi formation, and other 
disorders. Three months later, the patient was presented 
with lethargy. More evaluation showed macrocytic 
anemia (MCV> 95Hb =3/5), insulin-resistant diabetes 
(serum glucose> 400 mg/dl), and bilateral sensor neural 
deafness. Based on the clinical and paraclinical findings 
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Fig 1. Homozygosity in the patient is shown for the detected variant in SLC19A2 gene (c.204+2T>G) 
Fig 2. Heterozygosity in his father is shown for the detected variant in SLC19A2 gene (c.204+2T>G)
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Fig 3. Heterozygosity in his mother is shown for the detected variant in SLC19A2 gene (c.204+2T>G)
Fig 4. T2 Sequencing shows hypersignal
 changes in left temporoparietal region 
Fig 5. FLAIR sequencing shows 
hypointensity in left temporoparietal region 
Figure 4 & 5 shows Axial brain MRI in FLAIR & T2W sequence shows cystic encephalomalacia with peripheral gliosis 
in left MCA territory and right posterior watershed zone at parieto-occipital lobe consistent with remote stroke
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Discussion
TRMA syndrome is an autosomal recessive disorder 
caused by mutations in the SLC19A2 gene encoding 
the high-affinity thiamine transporter 1 (h-THTR1). 
Clinically, this syndrome is characterized by 
megaloblastic anemia, non-type I diabetes mellitus, and 
sensorineural deafness. In addition to the main clinical 
trial, some other clinical findings, such as abnormalities 
of the retina and optic nerve, congenital heart defects, 
short stature, and strokes have been described in a few 
cases. Most of patients were born from consanguineous 
parents (1, 7-10). In the present study, the patient’s 
parents were consanguineous. 
Typically, the current first line of therapy for patients with 
TRMA syndrome is pharmacological doses of thiamine 
(25-75 mg/d). Anemia and diabetes improve significantly 
with this treatment, although the erythrocytes may 
remain macrocytic. However, sensorineural hearing loss 
is apparently irreversible (2). In addition, some other 
clinical signs such as short stature seen in few cases may 
do not improve with thiamine administration (11).
In the present study, initially, the patient was presented 
with a history of focal seizure, and brain MRI results 
showed hemorrhagic stroke in right MCA region. Three 
months later the patient showed megaloblastic anemia, 
diabetes, and bilateral sensorineural deafness. Therefore, 
TRMA syndrome was established for the patient and 
additional management included thiamine repletion. 
Gradually macrocytic anemia and diabetes improved and 
MCV was decreased. In spite of thiamine administration, 
second stroke occurred. 
Strokes (or stroke-like episodes) are certain features of 
TRMA described in a few cases, even with homozygous 
null mutations (2). There is not any report of recurrent 
stroke after thiamine repletion. However, in the present 
study, the patient had stroke both before and after 
thiamine administration. 
TRMA is a genetic disorder caused by mutations in 
SLC19A2 on chromosome 1q23.3, that encodes a 
thiamine transporter protein. The disease can manifest at 
any time between infancy and adolescence. The majority 
of the mutations are null mutations because of nonsense 
or frameshift mutations. More than 28 mutations in 
SLC19A2 gene as heterozygote or homozygous have 
been reported leading to TRMA (2).
In the present study, molecular analyses identified a 
novel homozygous mutation c.204+2T>G on SLC19A2 
as the cause of the disease. A homozygous nonsense 
mutation c.697C>T (p.Gln233*) was described in 
Persian families with thiamine-responsive megaloblastic 
anemia, however, this mutation was previously reported 
in a Turkish patient, as well (11). 
In conclusion, more studies are needed to elucidate any 
association between TRMA and stroke as an outcome 
in this disease. The patient with stroke as a clinical 
manifestation did not respond to treatment very well.
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